RVX management is fearful their drug fails on one or more indications in the first round and really have no desire to push a timeline hard,,,,,the team is handsomely rewarded for the bulk of time over the span of a year ,,most of which is clearly inaction. 3rd parties know more about the MOA of apabetalone than does the team,,,its so obvious it hurts. Jmo.